Klinická farmakologie a farmacie – 3/2020

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2020; 34(3): 130–134 /  www.klinickafarmakologie.cz 134 HLAVNÍ TÉMA Léky indukované dysnatremie: I. Polékové hyponatremie ADH and hyponatremia with theophylline. Ann Pharmaco‑ ther, 2002; 36: 1180–1182. 12. Verghese C, de Leon J, Josiassen RC. Problems and pro‑ gress in the diagnosis and treatment of polydipsia and hy‑ ponatremia. Schizophr Bull. 1996; 22: 455–464. 13. Evenson RC, Jos CJ, Mallya AR. Prevalence of polydip‑ sia among public psychiatric patients. Psychol Rep. 1987; 60: 803–807. 14. Tan ECK, Lexomboon D, Sandborgh‑Englund G, Haasum Y, Johnell K. Medications That Cause Dry Mouth As an Ad‑ verse Effect in OlderPeople: A Systematic Review and Meta‑ analysis. J Am Geriatr Soc., 2018 ; 66(1): 76–84. 15. SPC. 16. Cersosimo MG, Raina GB, Calandra CR, Pellene A, Gutié‑ rrez C, Micheli FE, Benarroch EE., Dry mouth: an overlooked autonomic symptom of Parkinson’s disease., J Parkinsons, DiS. 2011; 1(2): 169–173. 17. Movig KLL, Leufkens HGM, Lenderink AW, Egberts ACG. Serotoninergic antidepressants associated with an increa‑ sed risk for hyponatraemia in the elderly. Eur J Clin Pharma‑ col, 2002; 58: 143–148. 18. Farmand S, Lindh J, Calissendorff J. Differences in associ‑ ations of antidepressants and hospitalization due to hypo‑ natremia, Am J Med, 2018; 131(1): 56–63. 19. Gandhi S, Shariff SZ, Al.Jaishi A, Reiss, JP, Mamdani MM, Hackam DG, Li L, McArthur E, Weir MA, Garg AX. Second­ ‑generation antidepressants and hyponatremia risk: a population‑based cohort study of older adults. Am J Kid‑ ney, DiS., 2017; 69: 87–96. 20. Rose BD, Post TW. Clinical Physiology of Acid‑Base and Electrolyte Disorders, ed 5. New York, McGraw‑Hill, 2001; 702. 21. Mogi T, Yoshono A, Ikemoto G, Nomura S. Mirtazapine as an alternative for selective serotonin reuptake inhibitor indu‑ ced syndrome of inappropriate secretion of antidiuretik hor‑ mon. Pharmacopsychiatry, 2007; 40: 129–131. 22. Cheah CY. Ladhams B, Fegan PG. Mirtazapine associated with profound hyponatremia:two case reports. Am J Geriatr Pharmacother., 2008; 6: 91–95. 23. Lien YH. Antidepressants and hyponatremia, Am J Med, 2018; 131(1): 7–8. 24. NazAli S, Bazzano LA. Hyponatremia in association with second‑generation antipsychotics: a systematic review of case reports, Ochsner Journal, 2018; 18: 230–235. 25. Van Amelsvoort T, Bakshi R, Devaus CB, Schwabe S. Hypo‑ natremia associated with carbamazepine and oxcarbamaze‑ pine therapy: A review. Epilepsia 35; 181–188, 1994. 26. Kuz GM, Manssourian A. Carbamazepine‑induced hy‑ ponatremia: Assesment of risk factor. Ann Pharmacother., 2005; 39: 1943–1946. 27. Bressler RB, Huston DP. Water intoxication following moderate‑dose intravenous cyclophosphamide. Arch In‑ tern Med 1985; 145: 548–549. 28. Pham L, Shaer AJ, Marnejon T. Hyponatremia- a rare but serious complication of amiodarone: a case report and re‑ view of the literature, Case rep Nephrol urol, 2013; 3: 46–50. 29. Brewster UC, Perazella MA: proton pump inhibitors and the kidney: Critical review. Clin Nephrol, 2007; 72: 65–72. 30. Holden R, Jackson MA. Near‑fatal hyponatremic coma due to vasopressin over‑secretion after „extasy“ (3,4,– methylene‑ diosymethylamphetamine). Lancet, 1996; 347: 1052. 31. Peters NA, Farrel LB, Smith JP. Hyperosmolar therapy for the treatment of cerebral edema, US Pharm, 2018; 43(1): 8–11. 32. Fandino W. Understanding the physiological changes induced by mannitol: From the theory to the clinical practi‑ ce in neuroanaesthesia, J Neuroanaesthesiol Crit Care, 2017; 4: 138–146. 33. Nomani AZ1, Nabi Z, Rashid H, Janjua J, Nomani H, Majeed A, Chaudry SR, Mazhar AS. Osmotic nephorisis with mannitol: Review article. Ren Fail., 2014; 36: 1169–1176.